Is Blackstone a Buy After Its Latest Earnings Report?

Blackstone (BX) reported Q3 AUM growth of 10% to $1.4T, with fee-related earnings up 6% to $1.6B. However, distributable earnings fell 9% due to lower net realizations. The company expects a reversal in Q4. Shares are down 28.5% from their 52-week high, trading at $117. Analysts see potential for 15% annualized returns over five years, considering earnings growth and dividend yield.

Original reporting
Published Oct 23, 2026, 5:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 6:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is Blackstone a Buy After Its Latest Earnings Report? — source image
Decision brief

The 30-second read

$BXBearishMed
01

Why it matters

The earnings miss and dividend cut may trigger short‑term selling, but the company's long‑term growth drivers (AI, private credit) could provide a floor for the stock.

02

Market read

First‑time disclosure of Blackstone's Q3 earnings, a large‑cap financial stock, with material earnings miss and dividend cut.

03

What to watch

Potential upside from expected Q4 net realizations and a 2027 earnings outlook not yet priced in.

Relevance 8/10Novelty 8/10Timing: after-hours reaction to Q3 earnings release

Background

Blackstone is a leading alternative asset manager with $1.4 trillion AUM; its earnings are closely watched for fee‑related growth versus earnings volatility.

Company-level read

Ticker impact

$BXBearishHigh confidence
Context

Blackstone reported Q3 results with AUM up 10% but distributable earnings fell 9% and dividend cut, providing fresh earnings data.

Expected impact

likely pressure as the market prices in lower earnings and dividend cut

Evidence & confidence

The article presents the first public disclosure of Blackstone's Q3 numbers, showing a 9% earnings decline and a dividend reduction, which typically triggers sell‑offs.

Market effects

Alternative asset managers may face scrutiny on fee‑related earnings volatility.

U.S. large‑cap financial sector could see modest pullback.

Limited to investors tracking private‑equity and credit exposure worldwide.

Counterpoint

Long‑term fee growth and AI investments could offset short‑term earnings volatility, supporting a buy‑the‑dip thesis.

Key entities

  • Michael Chea

    CFO who signaled higher net realizations in Q4.

  • Steve Schwarzman

    CEO who highlighted strong earnings power and outlook to 2027.

Related articles

$BXHigh

Blackstone's 16% Stake In IIFL Finance To Strengthen Capital Base

Blackstone Inc. plans to acquire a 16% stake in IIFL Finance, investing Rs 5,000 crore to boost its capital base. Fitch Ratings expects this to double IIFL Finance's Tier 1 capital ratio to 25.7% by September 2026, enhancing its funding flexibility and supporting growth plans. The transaction is not expected to immediately impact IIFL Finance's ratings or business model, which focuses on secured lending.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.